Repatha (Evolocumab) for ASCVD Secondary Prevention

What Is Evolocumab and How Does It Work?

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein produced mainly in the liver that degrades LDL receptors on hepatocyte surfaces. By blocking PCSK9, evolocumab allows more LDL receptors to remain active, pulling LDL cholesterol out of the bloodstream. The result is a pronounced, dose-dependent drop in circulating LDL-C that begins within days of the first injection [1].

Mechanism Relative to Statins

Statins upregulate LDL receptor expression but simultaneously increase PCSK9 production, which partially offsets their effect. Evolocumab blocks that compensatory PCSK9 rise, producing additive LDL-C reductions of 50% to 65% on top of statin therapy [2]. This complementary pharmacology explains why combining the two drug classes yields LDL-C levels that neither achieves alone.

Approved Indications

The FDA originally approved evolocumab in August 2015 for primary hyperlipidemia (heterozygous familial and non-familial) and homozygous familial hypercholesterolemia (HoFH) [3]. In December 2017, the FDA granted a supplemental approval specifically for reducing the risk of myocardial infarction, stroke, and coronary revascularization in adults with established ASCVD, based on the FOURIER trial results [4]. This means ASCVD secondary prevention is now an on-label, FDA-approved use, though some clinicians still encounter it described as "off-label" in older formulary documents written before the 2017 label expansion.

FOURIER Trial: The Primary Evidence Base

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) is the largest completed cardiovascular outcomes trial for any PCSK9 inhibitor, and it reshaped clinical practice for high-risk ASCVD management [5].

Study Design and Population

FOURIER was a randomized, double-blind, placebo-controlled trial enrolling 27,564 patients aged 40 to 85 with clinically evident ASCVD (prior MI, prior non-hemorrhagic stroke, or symptomatic peripheral artery disease) who were already on optimized statin therapy with fasting LDL-C of 70 mg/dL or higher (or non-HDL-C of 100 mg/dL or higher). Patients received either evolocumab (140 mg every 2 weeks or 420 mg monthly, patient's choice) or matching placebo. Median follow-up was 2.2 years [5].

Primary and Key Secondary Endpoints

The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of the placebo group, a 15% relative risk reduction (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). The key secondary endpoint, a harder composite of cardiovascular death, MI, or stroke, showed a 20% relative risk reduction (HR 0.80, 95% CI 0.73 to 0.88, P<0.001) [5].

Absolute Risk Reduction and NNT

The absolute risk reduction for the primary endpoint was 1.5 percentage points at 2.2 years, translating to a number needed to treat (NNT) of 67 over that period. Time-trend analyses showed greater separation of the Kaplan-Meier curves over time. By the second year onwards, the absolute risk difference for the key secondary endpoint widened to 2.0 percentage points, suggesting that longer treatment produces larger absolute benefits [5].

LDL-C Reductions Achieved

At 48 weeks, evolocumab reduced LDL-C by a median 59% from baseline (from median 92 mg/dL to 30 mg/dL). Approximately 42% of patients achieved LDL-C levels below 25 mg/dL. A prespecified analysis found a continuous, monotonic relationship between achieved LDL-C and cardiovascular event rates, with no attenuation of benefit at very low LDL-C levels and no excess adverse events [6].

Long-Term Follow-Up: FOURIER-OLE

Short trial durations invite the question of whether early benefits persist. The FOURIER Open-Label Extension (FOURIER-OLE) addressed this directly [7].

Design and Results

Of the original FOURIER cohort, 6,635 patients enrolled in the open-label extension, during which all participants received evolocumab. Over a median total follow-up of 5 years from initial randomization, patients originally assigned to evolocumab (early-start group) had a 15% lower rate of the key secondary composite of cardiovascular death, MI, or stroke compared with the late-start group (those who received placebo during FOURIER and then switched to evolocumab in OLE). As Dr. Michelle O'Donoghue of Brigham and Women's Hospital stated at the 2022 American College of Cardiology Scientific Sessions: "These data provide reassurance that the cardiovascular benefits of evolocumab are maintained over the long term and support an early treatment strategy for patients with ASCVD" [7].

Safety Over Five Years

No new safety concerns emerged with extended use. Rates of neurocognitive events, new-onset diabetes, cataracts, and hemorrhagic stroke were not elevated in patients who maintained very low LDL-C (median 30 mg/dL) for up to 5 years. Injection-site reactions remained mild and infrequent, reported in about 2.1% of evolocumab-treated patients versus 1.6% on placebo during the original trial [5][7].

Guideline Recommendations for PCSK9 Inhibitors in ASCVD

Multiple professional society guidelines have positioned PCSK9 inhibitors, including evolocumab, as step-up therapy in secondary prevention for patients who cannot reach LDL-C goals.

2018 AHA/ACC Cholesterol Guideline

The 2018 American Heart Association/American College of Cardiology multi-society guideline on blood cholesterol management classifies patients with established ASCVD into "high risk" and "very high risk" categories. For very-high-risk patients (those with multiple major ASCVD events or one major event plus multiple high-risk conditions) whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, the guideline states that "adding a PCSK9 inhibitor is reasonable" (Class IIa, Level of Evidence A) [8]. The guideline specifically cites the FOURIER and ODYSSEY OUTCOMES trials as the evidence base for this recommendation.

2019 ESC/EAS Dyslipidaemia Guidelines

The European Society of Cardiology and European Atherosclerosis Society set more aggressive LDL-C targets. For very-high-risk patients (including those with documented ASCVD), the 2019 ESC/EAS guidelines recommend an LDL-C goal of <55 mg/dL and at least a 50% reduction from baseline (Class I, Level of Evidence A). They recommend adding a PCSK9 inhibitor when combination therapy with maximally tolerated statin and ezetimibe fails to reach this target [9].

2022 ACC Expert Consensus Decision Pathway

The 2022 ACC Expert Consensus Decision Pathway for nonstatin therapies updated the clinical algorithm. It recommends considering a PCSK9 inhibitor for ASCVD patients whose LDL-C remains at or above 55 mg/dL on maximally tolerated statin plus ezetimibe, or for those who are ezetimibe-intolerant with LDL-C at or above 70 mg/dL. As the document notes: "For patients with ASCVD classified as very high risk, clinicians should not delay the addition of a PCSK9 inhibitor when LDL-C goals are not met" [10].

Dosing, Administration, and Practical Considerations

Evolocumab is administered as a subcutaneous injection. Two dosing schedules are approved, and both produce equivalent LDL-C reductions.

Dosing Options

Patients may choose between 140 mg every 2 weeks (using a single-dose prefilled SureClick autoinjector or prefilled syringe) or 420 mg once monthly (using three consecutive injections from the single-dose autoinjector or via the Pushtronex on-body infusor, which delivers the full 420 mg dose over approximately 5 minutes) [3]. In FOURIER, roughly two-thirds of patients chose the every-2-weeks schedule. Both regimens achieved median LDL-C reductions of 59% [5].

Injection Technique and Storage

The drug should be stored refrigerated at 2°C to 8°C (36°F to 46°F). A single prefilled autoinjector or syringe may be kept at room temperature (up to 25°C / 77°F) for a maximum of 30 days prior to use. Patients should rotate injection sites among the thigh, abdomen, and upper arm to minimize local reactions [3].

When to Expect Results

LDL-C reductions are measurable within 1 to 2 weeks and reach steady state by 12 weeks. A follow-up lipid panel at 4 to 12 weeks after initiation confirms response and guides clinical decision-making [8].

Who Is a Candidate for Evolocumab in ASCVD?

Not every patient with ASCVD needs a PCSK9 inhibitor. Guideline-directed selection focuses on patients at the highest residual risk.

Very-High-Risk ASCVD Criteria (per AHA/ACC)

A patient qualifies as very high risk if they have a history of multiple major ASCVD events (MI, ischemic stroke, or symptomatic PAD), or one major ASCVD event plus at least one high-risk condition. High-risk conditions include age 65 or older, heterozygous familial hypercholesterolemia, prior CABG or PCI, diabetes, hypertension, CKD (eGFR 15 to 59 mL/min/1.73m²), current smoking, persistently elevated LDL-C (100 mg/dL or more despite maximally tolerated statin plus ezetimibe), or history of congestive heart failure [8].

Statin Intolerance Scenarios

For patients with documented statin intolerance (confirmed by dechallenge/rechallenge or trial of at least two statins), evolocumab may be used at an earlier step in the treatment algorithm. The GAUSS-3 trial (N=511) demonstrated that evolocumab reduced LDL-C by 52.8% in statin-intolerant patients while ezetimibe achieved only 16.7%, with no excess musculoskeletal adverse events in the evolocumab arm [11].

Cost, Access, and Insurance Coverage

The economics of PCSK9 inhibitor therapy have changed substantially since initial launch.

Pricing History

Evolocumab launched in 2015 at a list price of approximately $14,100 per year. Amgen reduced the list price to roughly $5,850 per year in October 2018, a 60% reduction. Net pricing after rebates is estimated at $4,500 to $5,000 per year for commercially insured patients [12].

Insurance and Prior Authorization

Most commercial insurers and Medicare Part D plans cover evolocumab with prior authorization. Typical requirements include documentation of maximally tolerated statin therapy (or statin intolerance), concurrent use of or intolerance to ezetimibe, recent LDL-C values above goal, and a diagnosis of ASCVD or FH. Approval rates have improved from under 50% in 2016 to over 80% in recent years following the label expansion and price cut [12].

Patient Assistance

Amgen's Repatha Ready patient support program may reduce out-of-pocket costs to as low as $5 per month for eligible commercially insured patients. For uninsured patients, Amgen offers a patient assistance program providing the drug at no cost if income eligibility criteria are met [3].

Safety Profile in ASCVD Populations

Evolocumab's safety in cardiovascular patients has been evaluated across multiple trials and pooled analyses involving over 35,000 patient-years of exposure [5][7][13].

Common Adverse Effects

The most frequently reported adverse events in controlled trials include nasopharyngitis (5.9% vs. 4.8% placebo), upper respiratory infection (3.3% vs. 3.0%), and injection-site reactions (2.1% vs. 1.6%). These reactions are typically mild and rarely lead to discontinuation, with treatment discontinuation rates of 1.3% for evolocumab versus 1.4% for placebo in FOURIER [5].

Neurocognitive Safety

The EBBINGHAUS substudy (N=1,974), a prospective cognitive assessment nested within FOURIER, found no difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery (CANTAB) over a median of 19 months, including among patients who achieved LDL-C levels below 25 mg/dL [14]. This directly addressed earlier concerns raised by FDA advisory panels about very low LDL-C and cognition.

Immunogenicity

Binding antibodies to evolocumab developed in 0.3% of patients in clinical trials. No neutralizing antibodies were detected. The clinical significance of binding antibodies appears minimal, with no observed impact on efficacy or safety [3].

Evolocumab vs. Alirocumab: How the Data Compare

Alirocumab (Praluent), the other commercially available PCSK9 inhibitor, was tested in the ODYSSEY OUTCOMES trial (N=18,924) in post-acute coronary syndrome patients.

ODYSSEY OUTCOMES showed alirocumab reduced the primary composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina by 15% (HR 0.85, 95% CI 0.78 to 0.93) [15]. The magnitude of relative risk reduction is remarkably similar to FOURIER's 15% for the primary endpoint and 20% for the harder secondary endpoint. Head-to-head trials between the two PCSK9 inhibitors do not exist. Selection between them in practice often depends on formulary positioning, copay support, and patient preference for injection devices rather than efficacy differences [8][10].

Emerging Data and Ongoing Research

Several ongoing studies continue to refine the role of evolocumab in ASCVD management.

The VESALIUS-CV trial (NCT03872401, estimated N=13,000) is evaluating evolocumab in patients with ASCVD but without prior MI or stroke, specifically those with coronary stenosis, carotid stenosis, or PAD. Results are expected in 2026 and may expand the evidence base to a broader secondary-prevention population [16]. Imaging substudies from GLAGOV (N=968) have already demonstrated that evolocumab plus statin therapy produced coronary plaque regression in 64.3% of patients versus 47.3% on statin alone (P<0.001), with greater regression observed at lower achieved LDL-C levels [17].